

MEDICAL POLICY No. 91120-R5

FETAL SURGERY: INTRAUTERINE FETAL SURGERY; FETOSCOPIC LASER SURGERY

Effective Date: August 27, 2019

Date of Origin: July 16, 1990

Review Dates: 1/93, 2/95, 12/99, 12/01, 4/02, 4/03, 3/04, 3/05, 2/06, 6/06, 6/07, 4/08, 4/09, 4/10, 4/11, 8/11, 8/12, 8/13, 8/14, 8/15, 8/16, 8/17, 8/18, 8/19, 8/20, 8/21, 8/22, 8/23, 8/24 Status: Current

I. POLICY/CRITERIA

Fetal surgery may be considered medically necessary when evaluated and performed at fetal surgery centers which offer comprehensive evaluation, surgery, support services and follow-up. The following conditions may be considered for fetal surgery when meeting the below associated criteria and the criteria of the fetal surgery center:

- A. Vesico-amniotic shunting as a treatment of urinary tract obstruction for fetuses with hydronephrosis due to bilateral urinary tract obstruction when ALL of the following criteria are met:
 - 1. Evidence of progressive oligohydramnios
 - 2. Evidence of adequate renal function
 - 3. No other lethal abnormalities or chromosomal defects
 - 4. Male fetus
 - 5. No other maternal complications
- B. Either open in utero resection of malformed pulmonary tissue or placement of a thoraco-amniotic shunt as a treatment of congenital cystic adenomatoid malformation, extralobar pulmonary sequestration or pleural effusion when ALL of the following criteria are met:
 - 1. Fetuses of 32 weeks' gestation or less
 - 2. Evidence of fetal hydrops or high risk of high cardiac output
 - 3. No other lethal abnormalities or chromosomal defects
 - 4. No other maternal complications
- C. In utero removal of sacrococcygeal teratoma (SCT) when ALL of the following criteria are met:
 - 1. Fetuses of 32 weeks' gestation or less
 - 2. High risk of high cardiac output
 - 3. No other lethal abnormalities or chromosomal defects
 - 4. No other maternal complications

MEDICAL POLICY No. 91120-R5

- D. Fetoscopic laser coagulation as a treatment for severe twin-to-twin transfusion syndrome (TTTS) as medically necessary when ALL of the following criteria are met:
 - 1. The gestational age of the fetus is less than 26 weeks
 - 2. There is evidence of polyhydramnios in the recipient fetus
 - 3. The donor fetus is oligohydramniotic
 - 4. There is an absence of other fetal abnormalities
 - 5. No other maternal complications
- E. Fetal surgery is considered medically necessary for in utero repair of myelomeningocele when the following conditions are met:
 - 1. Singelton pregnancy; AND
 - 2. Myelomeningocele with the upper boundary of the lesion located between T1 and S1; AND
 - 3. Evidence of hindbrain herniation; AND
 - 4. Gestational age of 19.0 to 25.9 weeks; AND
 - 5. Normal fetal karyotype; AND
 - 6. Absence of ALL of the following:
 - i. Fetal anomaly unrelated to the myelomeningocele; AND
 - ii. Severe fetal kyphosis; AND
 - iii. Short cervix (less than or equal to 15 mm); AND
 - iv. Previous pre-term birth; AND
 - v. Placental abruption; AND
 - vi. Maternal Body Mass Index (BMI) greater than or equal to 35; AND
 - vii. Contraindications to surgery, including but not limited to previous hysterotomy in the active (upper) uterine segment.
- F. Other applications of fetal surgery are considered investigational, including but not limited to temporary tracheal occlusion as a treatment of congenital diaphragmatic hernia, fetal surgery for aqueductal stenosis (hydrocephalus), heart block, pulmonary valve or aortic obstruction, tracheal atresia or stenosis, and cleft lip and palate. In utero gene therapy and in utero stem cell transplantation are also considered to be experimental.

II. MEDICAL NECESSITY REVIEW

Prior authorization for certain drug, services, and procedures may or may not be required. In cases where prior authorization is required, providers will submit a request demonstrating that a drug, service, or procedure is medically necessary. For more information, please refer to the <u>Priority Health Provider Manual</u>.

III. APPLICATION TO PRODUCTS

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

- **HMO/EPO:** *This policy applies to insured HMO/EPO plans.*
- **POS:** *This policy applies to insured POS plans.*
- PPO: This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.
- ASO: For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.
- INDIVIDUAL: For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.
- MEDICARE: Coverage is determined by the Centers for Medicare and Medicaid Services (CMS) and/or the Evidence of Coverage (EOC); if a coverage determination has not been adopted by CMS, this policy applies.
- MEDICAID/HEALTHY MICHIGAN PLAN: For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: <u>http://www.michigan.gov/mdch/0,1607,7-132-</u> 2945 42542 42543 42546 42551-159815--,00.html. If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual located at: <u>http://www.michigan.gov/mdch/0,1607,7-132-2945 5100-87572--,00.html</u>, the Michigan Medicaid Provider Manual will govern. If there is a discrepancy or lack of guidance in the Michigan Medicaid Provider Manual, the Priority Health contract with Michigan Medicaid will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.

IV. DESCRIPTION

The objective of fetal surgery is to correct malformations of the fetus that interfere with organ development and fetal survival and have potentially fatal consequences. The specific techniques used for fetal surgery are determined by the diagnosis and specific circumstances of each individual case.

Intrauterine or in utero fetal surgery (IUFS):

Open fetal surgery involves making an incision through the abdomen of the mother and partial removal of the uterus from the body. Amniotic fluid is drained from the uterus and kept in a warmer for replacement after completion of the surgery. An incision is made in the uterus. Surgery is then performed on the fetus through the opening in the uterus to locate the abnormality and remove or fix it. Because of the nature of open fetal surgery, delivery for this child and all subsequent children of this mother will have to be performed by cesarean section.

MEDICAL POLICY No. 91120-R5

Fetal Surgery

Fetoscopic surgery: This type of surgery, which employs minimally invasive techniques, is used more often than open surgery. Surgeons can use fiberoptic telescopes and specially designed instruments to enter the uterus through small surgical openings to correct congenital malformations without major incisions or removing the fetus from the womb. This alternative is less traumatic and reduces the chances of preterm labor.

Fetoscopic laser surgery is a procedure for ablating abnormal vascular connections between monozygotic twins who share a single placenta and are affected by twintwin transfusion syndrome (TTTS). TTTS is a serious and potentially fatal complication resulting from an imbalance in net blood flow from one twin, the donor, to the other, the recipient. Laser energy is used to ablate the placental connecting vessels, thereby interrupting fetofetal blood flow and restoring circulatory balance. The goal of this procedure is to decrease the risk of intrauterine fetal and neonatal death and improve the outcomes of the surviving infants.

Fetal urinary-tract obstruction: Lower urinary obstruction in the fetus is an obstruction to the flow of urine out of the bladder, causing backup of urine and damage to the kidneys. The most common cause of bladder obstruction is posterior urethral valves in males although the condition may be linked to a genetic abnormality. The patient selection criteria for intervention are based upon fetalurine electrolyte studies, beta²-microglobulin levels and the use of ultrasound. The severity of damage at birth depends on the type, degree and duration of the obstruction. Conditions of minimal renal dysfunction and normal pulmonary development can be treated after delivery. Unilateral obstruction does not lead to oligohydramnios (decrease in amniotic fluid). However, bilateral urinary obstruction in the fetus is often associated with serious adverse outcomes, such as pulmonary hypoplasia secondary to oligohydramnios.

The most common surgical approach to repair the obstruction is vesicoamniotic shunting by means of a shunt or a stent inserted into the urinary tract above the obstruction and then passed through the abdominal wall to drain into the amniotic sac. This method of treatment restores amniotic fluid, preventing pulmonary hypoplasia.

Congenital cystic adenomatoid malformation (CCAM)/congenital pulmonary airway malformation (CPAM): Congenital cystic adenomatoid malformation, recently termed Congenital Pulmonary Airway Malformation (CPAM) is a benign cystic pulmonary mass that may lead to fetal hydrops and pulmonary hypoplasia. The CCAM/CPAM is typically unilateral and unilobular and receives blood supply from the pulmonary vasculature. The condition may result in air trapping and progressive respiratory compromise. Large lesions may cause mediastinal shift and fetal hydrops, pulmonary hypoplasia and persistent pulmonary hypertension. The mortality rate approaches 100% for cases in which both CCAM/CPAM and fetal hydrops are present, fortunately fetal hydrops occurs in fewer than 10% of cases.



MEDICAL POLICY No. 91120-R5

Most lesions can be successfully treated after birth, and some may resolve prior to birth; it is rare, however, that resolution of hydrops occurs in conjunction with regression of the lesion (Adzick, 1996). When large lesions are identified prior to 26 weeks of gestation, the disease progresses rapidly, ultimately resulting in fetal demise.

Sacrococcygeal teratoma (SCT): A sacrococcygeal teratoma is a tumor derived from more than one embryonic germ layer. Most tumors are benign, but the odds of malignancy increase with increasing age. In many cases, the abnormal size of the uterus (from either the tumor or polyhydramnios) leads to diagnosis by ultrasound. Less commonly, presentation may include maternal pre-eclampsia.

The standard treatment is complete excision after birth if not detected prenatally. When SCT is detected prenatally, early surgical intervention may be performed to prevent the development of fetal hydrops. These are extremely vascular tumors. Fetal hydrops develops as a result of vascular shunting between low-pressure vessels within the tumor, leading to cardiovascular collapse in cases of large lesions. Left uncorrected, SCT, when it occurs in conjunction with high output failure that is associated with placentomegaly or hydrops, results in 100% fetal mortality. Cardiac failure manifests as hydrops, association of fetal hydrops and SCT is usually fatal and always fatal prior to 30 weeks gestation (Gharpure, 2013). SCT types depend on their location, severity, and appearance: Type I: Almost completely external (outside the fetus) and attached to the tailbone; Type II: Mostly external, with a small part of the tumor growing inside the fetus; Type III: Visible externally, but with the tumor extending from the pelvis into the abdomen; Type IV: Completely internal. For some high-risk SCT fetuses, in utero open fetal surgery is an option at specialized centers. Although criteria for open fetal surgery vary across centers, most include fetuses with high-risk SCT and hydrops developing at a gestational age earlier than appropriate for delivery and neonatal care (eg, 28 to 32 weeks gestation) (UptoDate, 2024).

Extralobar pulmonary sequestration (EPS): Bronchopulmonary sequestration is a condition characterized by the presence of nonfunctioning lung tissue which is not connected to the tracheal bronchial tree. It may be intralobar or extralobar. The ability to determine the actual type of sequestration is very limited unless extralobar pulmonary sequestration (EPS) is associated with pleural effusion or is located in the abdomen. If not corrected, bronchopulmonary sequestration results in abnormal respiratory functioning and ultimately in fetal hydrops. Large lesions may cause esophageal compression, which may interfere with fetal swallowing of amniotic fluid and eventually result in polyhydramnios. Fetal hydrops develops secondary to vena caval obstruction and cardiac compression. Bronchopulmonary sequestration may also result in a tension hydrothorax from associated fluid or lymph secretion. In-utero correction involves placement of a thoracoamniotic shunt and is supported mainly by evidence on the form of case reports and reviews (Adzick, et al, 1998; Adzick, et al, 2003).

Page 5 of 12

MEDICAL POLICY No. 91120-R5

Pleural effusions: Isolated fetal pleural effusions have an incidence rate of approximately 1:10,000 to 15,000 pregnancies and may be bilateral but are most commonly unilateral. There are a variety of causes which include congenital abnormalities and chromosomal abnormalities. The persistence of pleural effusion in early pregnancy interferes with normal lung development and often results in pulmonary hypoplasia. Treatment consists of draining the intrathoracic fluid by the insertion of pleuro-amniotic shunts or by thoracentesis, where liquid is drained after single or multiple transthoracic punctures.

Twin-to-twin transfusion syndrome:

Twin-twin transfusion syndrome (TTTS) results from unbalanced blood flow through vascular arteriovenous anastomoses, which are present in the placenta of the majority of monochorionic multiple pregnancies. With preferential blood flow in severe cases, one twin becomes the donor and the other is the recipient, which may result in wide discordance in fetal growth.

The recipient twin, the larger fetus in the amniotic sac with polyhydramnios, typically has a large umbilical cord, abdominal circumference, kidneys, and bladder. Excessive volume can lead to cardiovascular decompensation with cardiomegaly, tricuspid regurgitation, and ventricular hypertrophy; hydrops fetalis may also develop. Polycythemia in the recipient fetus can lead to thrombosis or hyperbilirubinemia after birth.

The donor twin is the smaller fetus and is in the oligohydramniotic sac. This fetus may have severe growth restriction with anemia, hypovolemia, and renal insufficiency.

Standard interventions include amnioreduction and fetoscopic laser surgery performed percutaneously or through open surgery. The most severe cases are those diagnosed prior to 25 weeks of gestation.

The most widely used therapy for TTTS, amnioreduction, seeks to equalize the volume of amniotic fluid between the twins. This treatment involves serial amniocentesis and is recommended for pregnancies of gestation later than 26 weeks if delivery is not an option. Amnioreduction does not correct the underlying vascular abnormality. Survival rates have been reported to be between 50–65% with this intervention (Children's Hospital of Philadelphia [CHOP]).

Fetoscopic laser surgery corrects the underlying circulatory imbalance. The surgery may be performed through an open approach or percutaneously. Laser energy is used to ablate the placental anastomoses, thus interrupting fetal blood-flow transfusion and restoring the circulatory balance. The reported survival rates average 67%, with 80% of pregnancies having at least one survivor; laser photocoagulation is associated with reduced neurologic morbidity (CHOP).

Myelomeningocele: Myelomeningocele, commonly referred to as spina bifida, is a neural-tube defect in which the spinal cord forms but remains open, exposing the meninges and neural tube to the intrauterine environment. The defect may include abnormal positioning of the brain (Arnold-Chiari II malformation). A variety of medical problems may result from the open neural tube. These include, but are not limited to, physical and mental disabilities, deformity of the extremities, scoliosis, and urinary dysfunction or failure. Some researchers contend that the intrauterine exposure causes secondary trauma to the spinal cord.

Traditional treatment consists of surgical repair after delivery, with ventriculoperitoneal shunting. In-utero surgical repair to the fetus has been proposed as a way to improve neurological outcomes; however, the procedure's long-term effects on brain function have not been determined. Three types of fetal surgery are performed to treat myelomeningocele: fetoscopic myelomeningocele repair; maternal hysterotomy; and microsurgical, three-layered, fetal myelomeningocele repair (fetal patch repair). Myelomeningocele repair consists of closing the dura and skin over the exposed spinal cord. Data from the Management of Myelomeningocele Study (MOMS) compared the results of prenatal and postnatal myelomeningocele repair. After recruiting 183 of the planned 200 subjects the trial was stopped due to significantly improved clinical outcomes for the prenatal surgery group compared to the post-natal treatment group. In 2011, Adzick and colleagues published the results of this trial which included 158 subjects who completed up to 12 months follow-up; 134 of those subjects were also available for evaluation at 30 months. Individuals were randomized to receive myelomeningocele repair in-utero or repair following delivery. ACOG published a committee opinion (ACOG, 2013) acknowledging publication of the MOMS trial and the rigorous requirements for the study. ACOG noted further that maternal fetal surgery has significant implications and complications that may occur acutely, postoperatively, for the duration of the pregnancy and in subsequent pregnancies. The Committee recommends that treatment is only offered at facilities with the expertise, multidisciplinary teams, services and facilities to provide the intensive care required for these patients.

Fetal ventriculomegaly refers to ventricular enlargement that is diagnosed prenatally. It is one of the most common fetal anomalies. The diagnosis is made by ultrasound when the arterial diameter of the ventricle is more than 10 mm. Once it is diagnosed, further evaluation by detailed ultrasound, fetal MRI, and genetic studies is required (Alluhaybi, 2022). In the early 1980s, fetal intervention was explored with the intention of improving outcome (Manning, 1986). However, patient selection was poor. Prenatal surgical management of fetal ventriculomegaly is still limited and associated with high risks. In the prenatal management of fetal ventriculomegaly, the efficacy of intrauterine ventricular shunting procedures is still limited.

For inherited genetic diseases, fetal gene therapy offers the potential of prophylaxis against early, irreversible and lethal pathological change. Massaro (2018) studied neuronopathic Gaucher disease (nGD), caused by mutations in GBA. In adult patients, the milder form presents with hepatomegaly, splenomegaly and occasional lung and bone disease; this is managed, symptomatically, by enzyme replacement therapy. Using this model, fetal intracranial injection of adeno-associated virus (AAV) vector reconstituted neuronal glucocerebrosidase expression. Mice lived for up to at least 18 weeks, were fertile and fully mobile. Neurodegeneration was abolished and neuroinflammation ameliorated. Neonatal intervention also rescued mice but less effectively. To date, no clinical trials with human participants have been completed.

V. CODING INFORMATION

ICD-10 Codes:

Not specified - see criteria

HCPCS/CPT Codes:

* PA rules do not apply

- 36460* Transfusion, intrauterine, fetal
- 76941* Ultrasonic guidance for intrauterine fetal transfusion or cordocentesis, imaging supervision and interpretation
- 59012* Cordocentesis (intrauterine), any method
- 59015* Chorionic villus sampling, any method
- 59030* Fetal scalp blood sampling
- 59070* Transabdominal amnioinfusion, including ultrasound guidance
- 59072* Fetal umbilical cord occlusion, including ultrasound guidance
- 59074* Fetal fluid drainage (eg, vesicocentesis, thoracocentesis, paracentesis), including ultrasound guidance
- 59076 Fetal shunt placement, including ultrasound guidance
- 59897 Unlisted fetal invasive procedure, including ultrasound guidance (*Use this code in lieu of S codes for Priority Medicare or Medicaid claims. Explanatory notes must accompany all claims*)
- S2401 Repair, urinary tract obstruction in the fetus, procedure performed in utero
- S2402 Repair, congenital cystic adenomatoid malformation in the fetus, procedure performed in utero
- S2403 Repair, extralobar pulmonary sequestration in the fetus, procedure performed in utero
- S2404 Repair, myelomeningocele in the fetus, procedure performed in utero
- S2405 Repair of sacrococcygeal teratoma in the fetus, procedure performed in utero

S2411 Fetoscopic laser therapy for treatment of twin-to-twin transfusion syndrome *"S" codes not covered for Priority Medicare, Medicaid

Not covered:

- S2400 Repair, congenital diaphragmatic hernia in the fetus using temporary tracheal occlusion, procedure performed in utero
- S2409 Repair, congenital malformation of fetus, procedure performed in utero, not otherwise classified

VI. REFERENCES

- Adzick NS. Management of fetal lung lesions. Clin Perinatol. 2009 Jun;36(2):363-76.
- Adzick NS, Thom EA, Spong CY, Brock JW 3rd, Burrows PK, Johnson MP, Howell LJ, Farrell JA, Dabrowiak ME, Sutton LN, Gupta N, Tulipan NB, D'Alton ME, Farmer DL; MOMS Investigators. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 2011 Mar 17;364(11):993-1004.
- Alluhaybi AA, Altuhaini K, Ahmad M. Fetal Ventriculomegaly: A Review of Literature. Cureus. 2022 Feb 18;14(2):e22352. doi: 10.7759/cureus.22352. PMID: 35223331; PMCID: PMC8860673.
- American College of Obstetricians and Gynecologists. Maternal Fetal Surgery for Myelomeningocele repair. Number 720, September 2017. Committee Opinion; 130 (3); e164-e167,
- Araujo Júnior E, Tonni G, Chung M, Ruano R, Martins WP. Perinatal outcomes and intrauterine complications following fetal intervention for congenital heart disease: systematic review and meta-analysis of observational studies. Ultrasound Obstet Gynecol. 2016 Oct;48(4):426-433. doi: 10.1002/uog.15867. Epub 2016 Sep 15. PMID: 26799734.
- Biard JM et al. Long-term outcomes in children treated by prenatal vesicoamniotic shunting for lower urinary tract obstruction. Obstet Gynecol. 2005 Sep;106(3):503-8.
- Chauhan DP, Srivastava AS, Moustafa ME, Shenouda S, Carrier E. In utero gene therapy: prospect and future. Curr Pharm Des. 2004;10(29):3663-72. doi: 10.2174/1381612043382828. PMID: 15579062.
- Clayton DB, Brock JW 3rd. In utero intervention for urologic diseases. Nat Rev Urol. 2012 Feb 21;9(4):207-17. doi: 10.1038/nrurol.2012.9. PMID: 22349659.
- Emery SP, Narayanan S, Greene S. Fetal aqueductal stenosis: Prenatal diagnosis and intervention. Prenat Diagn. 2020 Jan;40(1):58-65. doi: 10.1002/pd.5527. Epub 2019 Jul 15. PMID: 31306500.
- Evans LL, Harrison MR. Modern fetal surgery-a historical review of the happenings that shaped modern fetal surgery and its practices. Transl Pediatr. 2021 May;10(5):1401-1417. doi: 10.21037/tp-20-114. PMID: 34189101; PMCID: PMC8192985.
- Friedman KG, Sleeper LA, Freud LR, Marshall AC, Godfrey ME, Drogosz M, Lafranchi T, Benson CB, Wilkins-Haug LE, Tworetzky W. Improved

Page 9 of 12

MEDICAL POLICY No. 91120-R5

technical success, postnatal outcome and refined predictors of outcome for fetal aortic valvuloplasty. Ultrasound Obstet Gynecol. 2018 Aug;52(2):212-220. doi: 10.1002/uog.17530. Epub 2018 Jul 4. PMID: 28543953.

- Gharpure V. Sacrococcygeal teratoma. J Neonatal Surg. 2013 Apr 1;2(2):28. PMID: 26023448; PMCID: PMC4420369
- Hayes Inc. Fetal Surgery For Myelomeningocele. Health Technology Assessment, Jul 23, 2018. Annual Review Sep 8, 2021.
- Hirose S, Farmer DL. Fetal surgery for sacrococcygeal teratoma. Clin Perinatol. 2003 Sep;30(3):493-506. doi: 10.1016/s0095-5108(03)00059-9. PMID: 14533891.
- Hedrick HL, Flake AW, Crombleholme TM, Howell LJ, Johnson MP, Wilson RD, Adzick NS. Sacrococcygeal teratoma: prenatal assessment, fetal intervention, and outcome. J Pediatr Surg. 2004 Mar;39(3):430-8; discussion 430-8. Hirose S, Farmer DL. Fetal surgery for sacrococcygeal teratoma. Clin Perinatol. 2003 Sep 1;30(3):493-506.
- Lopriore E et al. Neonatal outcome in twin-to-twin transfusion syndrome treated with fetoscopic laser occlusion of vascular anastomoses. J Pediatr. 2005 Nov;147(5):597-602.
- Luks FI, Johnson A, Polzin WJ; North American Fetal Therapy Network. Innovation in maternal-fetal therapy: a position statement from the North American Fetal Therapy Network. Obstet Gynecol. 2015 Mar;125(3):649-652.
- Manning FA, Harrison MR, Rodeck C. Catheter shunts for fetal hydronephrosis and hydrocephalus. Report of the International Fetal Surgery Registry. N Engl J Med. 1986 Jul 31;315(5):336-40. doi: 10.1056/NEJM198607313150532. PMID: 3724830.
- Moise KJ Jr, Moldenhauer JS, Bennett KA, Goodnight W, Luks FI, Emery SP, Tsao K, Moon-Grady AJ, Moore RC, Treadwell MC, Vlastos EJ, Wetjen NM. Current Selection Criteria and Perioperative Therapy Used for Fetal Myelomeningocele Surgery. Obstet Gynecol. 2016 Mar;127(3):593-597.
- Massaro G, Mattar CNZ, Wong AMS, Sirka E, Buckley SMK, Herbert BR, Karlsson S, Perocheau DP, Burke D, Heales S, Richard-Londt A, Brandner S, Huebecker M, Priestman DA, Platt FM, Mills K, Biswas A, Cooper JD, Chan JKY, Cheng SH, Waddington SN, Rahim AA. Fetal gene therapy for neurodegenerative disease of infants. Nat Med. 2018 Sep;24(9):1317-1323. doi: 10.1038/s41591-018-0106-7. Epub 2018 Jul 16. PMID: 30013199; PMCID: PMC6130799.
- Morris RK1, Malin GL, Quinlan-Jones E, Middleton LJ, Diwakar L, Hemming K, Burke D, Daniels J, Denny E, et al. The Percutaneous shunting in Lower Urinary Tract Obstruction (PLUTO) study and randomised controlled trial: evaluation of the effectiveness, cost-effectiveness and acceptability of percutaneous vesicoamniotic shunting for lower urinary tract obstruction. Health Technol Assess. 2013 Dec;17(59):1-232.
- Nationwide Children's Sacrococcygeal Teratoma (SCT). Available at <u>https://www.nationwidechildrens.org/conditions/sacrococcygeal-teratoma-sct</u> (Accessed June 24, 2024).

Page 10 of 12

MEDICAL POLICY No. 91120-R5

- Robry R, Quarello E, & Ville Y. Management of fetofetal transfusion syndrome. Prenat Diagn. 2005 Sep;25(9):786-95.
- Quintero RA. Twin to twin transfusion syndrome. Clin Perinatol. 2003 Sep;30(3):591-600.Rocha G, Fernandes P, Rocha P, Quintas C, Martins T, Proenca E. Pleural effusions in the neonate. Acta Paediatr. 2006 Jul;95(7):791-8.
- Senat MV et al. Endoscopic laser surgery versus serial amnioreduction for severe twin-to-twin transfusion syndrome. N Engl J Med. 2004 Jul 8;351(2):136-44.
- University of California, Davis. Fetal Care and Treatment Center. Sacrococcygeal teratoma. Available at <u>https://health.ucdavis.edu/children/services/fetal-care-treatment-center/conditions-we-treat/sacrococcygeal-teratoma</u> (Accessed June 24, 2024).
- Trigo L, Chmait RH, Llanes A, Catissi G, Eixarch E, Van Speybroeck A, Lapa DA. Revisiting MOMS criteria for prenatal repair of spina bifida: upper gestational-age limit should be raised and assessment of prenatal motor function rather than anatomical level improves prediction of postnatal function. Ultrasound Obstet Gynecol. 2024 Jan;63(1):53-59. doi: 10.1002/uog.27536. PMID: 37970655.
- UptoDate. Fetal cardiac abnormalities: Screening, evaluation, and pregnancy management. Author: Copel J. Editors: Wilkins-Haug L, Levine D. Topic last updated March 29, 2019.
- UpToDate. Overview of the management of myelomeningocele (spina bifida). Author: Bowman RM. Editors: Patterson MC, Weisman LE, Duryea TK. Topic last updated Feb 27, 2020.
- UpToDate. Twin-twin transfusion syndrome: Management and outcome. Author: Papanna R. Editors: Levine D, Simpson LL. Topic last updated May 6, 2020.
- UpToDate. Sacrococcygeal teratoma. Authors:Rachel A Egler, MDLouise Wilkins-Haug, MD, PhD. Literature review current through: May 2024. This topic last updated: Dec 08, 2023.
- Van Mieghem T, Al-Ibrahim A, Deprest J, Lewi L, Langer JC, Baud D, O'Brien K, Beecroft R, Chaturvedi R, Jaeggi E, Fish J, Ryan G. Minimally invasive therapy for fetal sacrococcygeal teratoma: case series and systematic review of the literature. Ultrasound Obstet Gynecol. 2014 Jun;43(6):611-9. doi: 10.1002/uog.13315. Epub 2014 May 8. PMID: 24488859.
- von Koch CS, Gupta N, Sutton LN, Sun PP. In utero surgery for hydrocephalus. Childs Nerv Syst. 2003 Aug;19(7-8):574-86. doi: 10.1007/s00381-003-0775-4. Epub 2003 Jul 25. PMID: 12955423.
- WAPM Consensus Group on Twin-to-Twin Transfusion, Baschat A, Chmait RH, Deprest J, Gratacós E, Hecher K, Kontopoulos E, Quintero R, Skupski DW, Valsky DV, Ville Y. Twin-to-twin transfusion syndrome (TTTS). J Perinat Med. 2011 Mar;39(2):107-12
- Wu S, Johnson MP. Fetal lower urinary tract obstruction. Clin Perinatol. 2009 Jun;36(2):377-90.
- Yadav DK, Acharya SK, Bagga D, Jain V, Dhua A, Goel P. Sacrococcygeal Teratoma: Clinical Characteristics, Management, and Long-term Outcomes in Page 11 of 12



MEDICAL POLICY No. 91120-R5

Fetal Surgery

a Prospective Study from a Tertiary Care Center. J Indian Assoc Pediatr Surg. 2020 Jan-Feb;25(1):15-21. doi: 10.4103/jiaps.JIAPS_219_18. Epub 2019 Nov 27. PMID: 31896894; PMCID: PMC6910050.

Zanjani ED, Anderson WF. Prospects for in utero human gene therapy. Science. 1999 Sep 24;285(5436):2084-8. doi: 10.1126/science.285.5436.2084. PMID: 10523208.

AMA CPT Copyright Statement:

All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion.

Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.

Page 12 of 12